Lupin Ltd.

Lupin Ltd., a prominent mid-cap player in the Pharmaceuticals & Biotechnology sector, witnessed significant trading activity on 10 Aug 2026, with over 24 lakh shares exchanging hands and a total traded value exceeding ₹55,160 lakhs. Despite this high-value turnover, the stock has experienced a notable decline over the past four sessions, underperforming its sector and broader market indices.

Lupin Ltd., a mid-cap pharmaceutical heavyweight, has witnessed a significant 30.26% surge in open interest (OI) in its derivatives segment, even as the stock price declined by 3.43% on 10 Aug 2026. This divergence between rising derivatives activity and falling spot prices signals evolving market positioning and potential directional bets among traders, warranting a closer examination of volume patterns, investor sentiment, and technical indicators.

Lupin Ltd. experienced a notable decline today, touching an intraday low of Rs 2,236, reflecting a 5.25% drop as the stock faced significant price pressure and underperformed its sector peers in the Pharmaceuticals & Biotechnology industry.

Lupin Ltd., a mid-cap pharmaceutical and biotechnology company, has witnessed a significant surge in open interest (OI) in its derivatives segment, rising by 24.29% to 46,619 contracts from 37,509. This spike comes despite the stock’s recent underperformance, including a 5.07% decline on 10 Aug 2026 and a four-day consecutive fall totalling a 7.01% loss. The divergence between derivatives activity and spot price movement signals evolving market positioning and potential directional bets among traders.

Lupin Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 16.46% surge in open interest in its derivatives segment, even as the stock price declined by over 4% on 10 Aug 2026. This divergence between rising open interest and falling price signals evolving market positioning and potential directional bets among traders, warranting a closer examination of volume patterns, investor sentiment, and technical indicators.

Lupin Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 12.55% surge in open interest in its derivatives segment, even as the stock price declined by 3.53% on 10 Aug 2026. This divergence between rising open interest and falling prices signals evolving market positioning and potential directional bets among traders, warranting a closer examination of volume patterns, investor sentiment, and technical indicators.

Lupin Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, transitioning from a bullish to a mildly bullish trend. Despite a recent dip of 1.32% in its share price to ₹2,360.00, the stock continues to demonstrate resilience amid mixed signals from key technical indicators such as MACD, RSI, and moving averages.

Lupin Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an attractive to a very attractive rating. This change reflects improved price metrics relative to its historical averages and peer group, signalling a compelling opportunity for investors amid a mixed sector backdrop.

Lupin Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a significant 28.8% surge in open interest (OI) in its derivatives segment, signalling heightened market activity and evolving investor positioning. Despite this, the stock has underperformed its sector and the broader market, reflecting a complex interplay between derivative market enthusiasm and underlying price momentum.

Lupin Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a significant 22.8% surge in open interest in its derivatives segment, signalling heightened market activity and evolving positioning among traders. Despite this, the stock has underperformed its sector and broader indices, reflecting a complex interplay between investor sentiment and technical factors.

Lupin Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 18.35% surge in open interest (OI) in its derivatives segment, signalling heightened market activity and shifting positioning. Despite this, the stock has underperformed its sector and the broader Sensex, reflecting a complex interplay between investor sentiment and price dynamics.

Lupin Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 17.16% surge in open interest in its derivatives segment, signalling increased market activity and shifting investor positioning. This development comes alongside a modest price gain and mixed technical indicators, prompting a closer examination of the underlying market dynamics and potential directional bets.

Lupin Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has reported a positive financial performance for the quarter ended June 2026, signalling sustained growth momentum despite a slight moderation in its financial trend score. The company’s latest results highlight robust revenue expansion, margin resilience, and strong operational metrics that continue to underpin its mid-cap valuation and investor confidence.

Lupin Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable surge in open interest (OI) in its derivatives segment, signalling a shift in market positioning and potential directional bets. The stock outperformed its sector peers on 7 Aug 2026, reflecting renewed investor interest amid evolving volume and price dynamics.

Lupin Ltd., a mid-cap pharmaceutical heavyweight, has witnessed a notable 16.8% surge in open interest (OI) in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a marginal dip in the stock price, the underlying volume and futures data suggest a complex interplay of directional bets and cautious optimism among traders.

Lupin Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Buy to Strong Buy by MarketsMojo as of 3 August 2026. This upgrade reflects significant improvements across four key parameters: Quality, Valuation, Financial Trend, and Technicals. The company’s strong quarterly performance, attractive valuation metrics, and bullish technical indicators have collectively driven this positive reassessment.

Lupin Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 13.55% increase in open interest (OI) in its derivatives segment, signalling heightened market activity despite the stock’s recent underperformance. This surge in OI, coupled with volume patterns and price movements, offers valuable insights into evolving market positioning and potential directional bets among investors.

Lupin Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 12.6% surge in open interest in its derivatives segment, signalling heightened market activity and shifting positioning despite the stock’s recent underperformance. This development comes amid a three-day losing streak and a 3.3% decline in returns, raising questions about the underlying directional bets and investor sentiment.